
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Etoricoxib</title>
    <link rel="shortcut icon" href="images/testlogo.png" type="image/x-icon">
    <link rel="stylesheet" href="css.css">
    <style>
        body {
            background-color: rgba(196, 241, 255, 0.562);
        }
        .container {
            text-align: center;
            margin-left: 100px;
            margin-right:100px;
        }
        p {
            font-size: 22px; /* Adjust the font size as desired */
            font-style: italic;
            text-align: justify;
            text-justify: inter-word;
          }
          table {
         border-spacing: 30px;
          }
    </style>
</head>
<body>
    <center>
        <h1>ETORICOXIB</h1><br>
        <table>
            <tr>
                <td><img src="https://www.biobrickpharma.com/wp-content/uploads/2018/01/BICOXIB-90-3.jpg

                    " alt=""></td>
            
            </tr>
        </table>
            <div class="container">
                <p>price:140 Etoricoxib (Arcoxia, Merck&Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) class of nonsteroidal antiinflammatory drugs (NSAIDs). </p>
            </div>
    </center>
    
</body>
</html>